Sandra C.
- Country
- Germany
- Department
- Hämatologie/Onkologie
Research Overview
- Evaluation of Tafasitamab in Pediatric Patients with Relapsed or Refractory Acute B Lineage Leukemia: A Phase I/II, Single-Arm, Open-Label, Multicenter Study
- Phase 1/2 Multicenter Study of Belumosudil Mesilate in Pediatric Patients with Moderate-to-Severe Chronic Graft Versus Host Disease
- A Phase 2, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Pediatric Chronic Graft-Versus-Host Disease Post Two Systemic Therapies
Data & Insights
Has run more than one trial at 9 of 34 partner sites.
Specializations
Pediatric Oncology
The investigator specializes in treating childhood leukemia, with particular emphasis on developing innovative therapeutic approaches for young patients with blood cancers.
- Acute B-lineage leukemia
- Relapsed/refractory disease management
- Targeted therapy approaches
Their research focuses on evaluating novel therapeutic agents for pediatric patients with challenging blood disorders.
Hematologic Malignancies
The investigator concentrates on understanding and treating blood cancers with specific attention to disease monitoring and progression assessment.
- Minimal residual disease monitoring
- Bone marrow assessment
- Hematological relapse patterns
Their work includes developing strategies for early detection and management of disease recurrence.
Therapeutic Innovation
The investigator explores novel treatment modalities in pediatric hematology, particularly focusing on targeted therapeutic approaches.
- Monoclonal antibody therapy
- Treatment safety assessment
- Multicentre clinical research
Their expertise extends to evaluating innovative treatments for complex pediatric blood disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.